


## TC-2559 difumarate

Cat. No.:	HY-136207
CAS No.:	2454492-41-0
Molecular Formula:	C <sub>20</sub> H <sub>26</sub> N <sub>2</sub> O <sub>9</sub>
Molecular Weight:	438.43
Target:	nAChR
Pathway:	Membrane Transporter/Ion Channel; Neuronal Signaling
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



### BIOLOGICAL ACTIVITY

<b>Description</b>	TC-2559 idifumarate is a CNS-selective, orally active $\alpha 4\beta 2$ subtype of nicotinic acetylcholine receptor (nAChR) partial agonist ( $EC_{50}=0.18 \mu M$ ). TC-2559 difumarate shows selectivity for $\alpha 4\beta 2$ over $\alpha 2\beta 4$ , $\alpha 4\beta 4$ and $\alpha 3\beta 4$ receptors, with $EC_{50}$ s in the range of 10-30 $\mu M$ . Antinociceptive effect <sup>[1][2]</sup> .																
<b>In Vivo</b>	<p>TC-2559 difumarate (1-10 mg/kg; i.p.) dose dependently reduces acute formalin-induced biphasic nociceptive responses in mice<sup>[2]</sup>.</p> <p>TC-2559 difumarate (0.3-3 mg/kg; i.p.) dose dependently inhibits CCI-induced neuropathic pain in rats<sup>[2]</sup>. MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>Adult male mice (body weight 15-30 g) (formalin test)<sup>[2]</sup></td> </tr> <tr> <td>Dosage:</td> <td>1, 3, 10 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>i.p.</td> </tr> <tr> <td>Result:</td> <td>Dose dependently reduced both early and late phases of formalin induced nociceptive behavioral responses.</td> </tr> </table> <table border="1"> <tr> <td>Animal Model:</td> <td>Adult male SD rats (body weight 200-220 g) (chronic constriction injury (CCI))<sup>[2]</sup></td> </tr> <tr> <td>Dosage:</td> <td>0.3, 1, 3 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>i.p.</td> </tr> <tr> <td>Result:</td> <td>Significantly reversed CCI induced the paw withdrawal threshold decreases.</td> </tr> </table>	Animal Model:	Adult male mice (body weight 15-30 g) (formalin test) <sup>[2]</sup>	Dosage:	1, 3, 10 mg/kg	Administration:	i.p.	Result:	Dose dependently reduced both early and late phases of formalin induced nociceptive behavioral responses.	Animal Model:	Adult male SD rats (body weight 200-220 g) (chronic constriction injury (CCI)) <sup>[2]</sup>	Dosage:	0.3, 1, 3 mg/kg	Administration:	i.p.	Result:	Significantly reversed CCI induced the paw withdrawal threshold decreases.
Animal Model:	Adult male mice (body weight 15-30 g) (formalin test) <sup>[2]</sup>																
Dosage:	1, 3, 10 mg/kg																
Administration:	i.p.																
Result:	Dose dependently reduced both early and late phases of formalin induced nociceptive behavioral responses.																
Animal Model:	Adult male SD rats (body weight 200-220 g) (chronic constriction injury (CCI)) <sup>[2]</sup>																
Dosage:	0.3, 1, 3 mg/kg																
Administration:	i.p.																
Result:	Significantly reversed CCI induced the paw withdrawal threshold decreases.																

### REFERENCES

[1]. Bencherif M, et al. TC-2559: a novel orally active ligand selective at neuronal acetylcholine receptors. *Eur J Pharmacol.* 2000;409(1):45-55.

[2]. Cheng LZ, et al. Enhanced inhibitory synaptic transmission in the spinal dorsal horn mediates antinociceptive effects of TC-2559. *Mol Pain.* 2011;7:56. Published 2011 Aug 4.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA